

RAPID HEALTH TECHNOLOGY ASSESSMENT OF GAZELLE FOR SICKLE CELL DISEASE/TRAIT DIAGNOSIS AMONG HIGH-RISK POPULATION IN INDIA

ICMR-National Institute of Research in Reproductive and Child Health, Mumbai
A Regional Resource Hub for Health Technology Assessment in India

Recommendations:

- Gazelle is a highly sensitive Point of care (POC) test for screening Sickle cell disease (SCD) with confirmation of all positive cases with HPLC test at public healthcare settings.
- At current price of Gazelle machine (INR 2.5 lakhs) and per kit price (INR 180), the cost per case detected using Gazelle followed by confirmation with HPLC is INR 19062.64 as compared to Solubility test with HPLC which is INR 7762.29
- At INR 40 per test kit and INR 90,000 cost of Gazelle machine the cost per case detected of Gazelle with confirmation by HPLC would be at par with the existing cost of Solubility followed by confirmation with HPLC

Background

- Sickle Cell Disease (SCD) is a common genetic disorder prevalent in states of India's central region such as Madhya Pradesh, Chhattisgarh, Bihar, Odisha, Gujarat, Maharashtra Tamil Nadu, and Karnataka. SCD is most frequent among tribal communities.
- The National Sickle cell elimination mission (2023) aims to eliminate SCD as a public health problem in India before 2047. The prevention strategy of universal screening and early detection is a part of the objectives of this mission.
- Solubility test followed by confirmation with Electrophoresis/HPLC is the standard screening modality in public healthcare settings.
- Several Point of Care tests such as Hemotype Sc, Sickle Scan and Sickle CERT have been introduced in India that can differentiate between disease or trait and sickle- β -thalassemia.
- Gazelle, is a HemeChip cellulose acetate paper-based microchip electrophoresis system consisting of a Gazelle reader and Cartridge manufactured by Hemex Health India (Rajasthan).
- Gazelle is also one of the POC test that it capable of differentiating between disease or trait and sickle- β -thalassemia. The sensitivity for Gazelle test is 100% and its specificity is 99%.
- A Health Technology Assessment was recommended to be carried out to assess the cost per case screened and detected for Gazelle in screening for sickle cell disease/trait.

Key Findings:

- Even though the cost of Gazelle is high, in the study cohort, Gazelle detected 37365 more cases of SCD compared to the Standard of Care (SOC), Solubility test followed by confirmation with HPLC.
- The total health system costs of the screening program at public healthcare settings for Gazelle followed by confirmation with HPLC at current price would be INR 1271.93 crores. The health system costs for the comparator Solubility test with confirmation by HPLC is INR 488.92 crores.
- The marginal costs of implementing the screening program for Gazelle followed by confirmation with HPLC for a cohort of 39954483 is estimated to be INR 1040.00 crores and for Solubility test followed by confirmation with HPLC would be INR 322.03 crores.

Aim

- To conduct a Health Technology Assessment on point of care screening device Gazelle for Sickle cell disease/ traits.

Purpose

- To collate evidence on clinical-effectiveness of Gazelle vs Solubility test followed by confirmation with HPLC to diagnose sickle cell trait/disease
- To estimate cost of test per case screened and detected using Gazelle
- To assess the health system costs of using Gazelle for facility-based screening

PICO	Description of the components of PICO
Population	A tribal population cohort from 6 weeks to 40 years from six endemic states (Madhya Pradesh, Maharashtra, Gujarat, Tamil Nadu, Odisha and Chhattisgarh)
Intervention	Sickle cell screening with Gazelle test followed by confirmation with HPLC test
Comparator	Sickle cell screening with Solubility followed by confirmation with HPLC
Outcome	1. Cost per case screened 2. Cost per case detected 3. Additional number of cases detected

Figure 1: Representation of the Gazelle test




Table 1: Health system and marginal costs for screening program of SCD in India

Parameters	Gazelle + HPLC	Solubility + HPLC
Health system costs of rolling out the screening program	INR 1271.93 crores	INR 488.92 crores
Marginal costs for rolling out the screening program	INR 1040.00 crores	INR 322.03 crores

Table 1: Outcomes for screening program of SCD in India

Parameter	Values (All cost in INR)
Cost per case screened	
Gazelle + HPLC	INR 318.35 (158.86, 474.62)
Solubility + HPLC	INR 122.37 (60.00, 181.90)
Cost per case detected	
Gazelle + HPLC	INR 19,062.24 (9565.08, 28229.49)
Solubility + HPLC	INR 7762.29 (3691.15, 11839)
Additional number of cases detected by Gazelle + HPLC vs Solubility + HPLC	37365.43 (18809.05, 56400.91)

Conclusion:

- HPLC is the gold standard for sickle cell disease screening but access to this strategy for mass screening is limited. Gazelle has performance efficiency similar to HPLC. In comparison with HPLC, Gazelle takes less time to obtain the results. The cost for the machine is also less than HPLC. Gazelle does not require the expertise for performing and interpreting the test as it is required for HPLC. Therefore, a public health facility-based screening of high risk populations with Gazelle as a POC test would improve access to screening using a highly sensitive test.
- This test can also be used to diagnose thalassemia. It is essential to plan a multi-centric study for further evaluation on the application of Gazelle for screening neonates for SCD and diagnosis of thalassemia.



This policy brief and other related document can be downloaded using QR link provided above